Dyax Corp. (NASDAQ:DYAX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications.

Recs

0
Player Avatar misterp946 (< 20) Submitted: 5/22/2007 3:41:43 PM : Outperform Start Price: $4.34 DYAX Score: -51.98

Hot New Products....stock took a beating....when Genzyme deal feel through...This stock due for a nice come back....sell on announcement

Featured Broker Partners


Advertisement